About Korro Bio
Korro Bio develops RNA-based therapies aimed at treating serious diseases that currently lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes in protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can bring to market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to make significant scientific advancements in medicine accessible to patients in need.
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Company Equity
Risks
Potential competition from Beam Therapeutics in RNA editing technologies.
Merger with Frequency Therapeutics may lead to integration challenges.
Stock price surge could lead to increased scrutiny and volatility.
Differentiation
Korro Bio uses RNA editing for precise protein function modifications.
Their platform targets diseases with limited or no current treatment options.
Korro Bio's RNA editing is considered superior to traditional gene editing.
Upsides
Korro Bio raised $70M for clinical trials and growth in April 2024.
Partnership with Novo Nordisk targets cardiometabolic diseases like obesity and diabetes.
Recent FDA approval of RNA therapy may accelerate Korro Bio's regulatory pathway.
Funding
PRIVATE PLACEMENT VC
3/31/2024- MP Healthcare Venture Management
- Sixty Degree Capital
- Tri Locum Partners
- Invus
- Verition Fund Management
- Cormorant Asset Management
- Qiming Venture Partners USA
- Platanus
- Eventide Asset Management
- Blue Owl Capital
- Surveyor Capital
- NEA
- Monashee Investment Management
- New Enterprise Associates
- Point72 Ventures
- Deep Track Capital
- Rock Springs Capital
- Atlas Venture
SERIES B
12/31/2021- MP Healthcare Venture Management
- Sixty Degree Capital
- Invus
- Verition Fund Management
- Cormorant Asset Management
- Wu Capital
- Qiming Venture Partners USA
- Eventide Asset Management
- Alexandria Venture Investments
- Surveyor Capital
- NEA
- Monashee Investment Management
- Point72
- New Enterprise Associates
- Fidelity Investments
- Atlas Venture